Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Requirement of Analgesics After Two Remifentanil Dosing Regimen in Cardiac Surgery. (REMISYD)

This study has been completed.
Information provided by (Responsible Party):
Pasi Lahtinen, Kuopio University Hospital Identifier:
First received: September 22, 2008
Last updated: September 11, 2013
Last verified: September 2013
Prospective double blind study comparing two remifentanil dosing protocols (0.1 and 0.3 mcg/kg/min) during cardiac surgery. Main outcome measures are postoperative opioid requirements (PCA oxycodone) and postoperative pain (VAS, verbal rating scale).

Condition Intervention Phase
Drug: remifentanil
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Requirement of Analgesics After Two Remifentanil Dosing Regimen in Cardiac Surgery.

Resource links provided by NLM:

Further study details as provided by Pasi Lahtinen, Kuopio University Hospital:

Primary Outcome Measures:
  • Postoperative opioid (oxycodone) consumption [ Time Frame: Postoperatively 48 hours ]

Enrollment: 90
Study Start Date: September 2008
Study Completion Date: December 2011
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
remifentanil o.1 mcg/kg/min
Drug: remifentanil
remifentanil infusion
Active Comparator: 2
remifentanil 0.3 mcg/kg/min
Drug: remifentanil
remifentanil infusion


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Coronary artery bypass grafting patients

Exclusion Criteria:

  • Psychiatric disorders, sleep apnea, cardiac insufficiency
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00757198

Kuopio University hospital
Kuopio, Finland, 70210
Sponsors and Collaborators
Kuopio University Hospital
Study Director: Pasi Lahtinen, MD Department of Anesthesiology and Intensive Care, Kuopio University hospital, Kuopio, Finland
  More Information

Responsible Party: Pasi Lahtinen, PhD,MD, Kuopio University Hospital Identifier: NCT00757198     History of Changes
Other Study ID Numbers: KUH5070206
EudraCT 2008-000597-21
Study First Received: September 22, 2008
Last Updated: September 11, 2013

Keywords provided by Pasi Lahtinen, Kuopio University Hospital:
pain, postoperative, opioid, PCA, cardiac surgery

Additional relevant MeSH terms:
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Hypnotics and Sedatives
Anesthetics, Intravenous
Anesthetics, General
Anesthetics processed this record on May 25, 2017